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ABSTRACT 
Objective: The present study was done to evaluate repeated-dose 90-day oral toxicity studies of l-dopa and hyoscine hydrbromide combination in rats.  
Methods: Repeated-dose 90-day oral toxicity study was performed according to the Organisation for Economic Co-operation and 
Development (OECD) guidelines 408. In the present study, combination of L-dopa and hyoscine hydrobromide was administered at 5 times the 
upper limit of therapeutic dose of each drug which is 1200 mg per day for L-dopa and 0.75 mg per day for hyoscine hydrobromide for adult human 
being and which was converted to required dose for Wistar rats (5 males and 5 females).  
Results: The combination of L-dopa and hyoscine hydrobromide at 5 times the upper therapeutic dose produced no treatment-related signs of 
toxicity or mortality in any of the animals tested during 90 d of the study. The subchronic administration of the combination of L-dopa and hyoscine 
hydrobromide did not produce any significant difference in any of the assigned parameters between the control and all treatment groups. 
Conclusion: It is established that the combination of L-dopa and hyoscine hydrobromide therapy is safe on repeated dose 90-day oral toxicity at 5 
times the upper limit of therapeutics dose of each drug.  
Keywords: Parkinson’s, Toxicity, L-dopa, Hyoscine hydrobromide. 
 
INTRODUCTION 
Parkinson’s disease (PD) is primarily a dopamine (DA) deficiency 
progressive neurodegenerative disease in which there is extensive 
loss of nigrostriatal dopamine-containing neurons in the substantia 
nigra (SN) and this is the main cause of pathological change [1, 2] 
and the deposition of α-synuclein intracellularly throughout the 
nervous system [3]. This is characterized by muscle rigidity, 
tremors, bradykinesia, and postural abnormalities due to loss of 
dopamine [5]. Since dopamine cannot cross the blood–brain barrier, 
L-3, 4-dihydroxyphenylalanine (L-dopa), It’s natural and direct 
precursor is the most effective and widely used gold standard 
medication for PD. L-DOPA was first used in clinical trials in 1967 
wherein it was reported to result in the therapeutic success in the 
treatment of PD and a number of DA receptor agonists have been 
introduced for the treatment of PD [4-6].  
On the other hand, L-DOPA therapy develops tolerance in 
Parkinson’s patients on long term use resulting in the need for 
increased doses over time [7]. Eventually the drug raises various 
side effects particularly motor complications including L-DOPA-
induced dyskinesias (LID) [8], motor fluctuations and the wearing 
off phenomenon [9]. This motor control fluctuation can be 
controlled by administering antimuscarinic drugs such as 
benztropine, scopolamine which act by blocking the excitatory 
cholinergic neurons in the neo striatum thereby assisting in 
establishing correct dopamine/acetylcholine balance. Scopolamine 
has the additional advantage of reducing nausea and vomiting, a 
prominent side effect of Levodopa [10]. 
Hyoscine hydrobromide, an antimuscarinic alkaloid has the 
strongest pharmacological effect, can be used to block the 
parasympathetic nerve. Hyoscine hydrobromide has been used for 
stiff and tremor symptom of parkinsonian syndrome; however, 
antimuscarinics generally have been replaced with dopaminergic 
drugs [11]. 
Despite their widespread use, little toxicological data is available 
regarding the safety of repeated use of the combination of L-dopa 
and hyoscine hydrobromide. Available data are insufficient to 
support the safety of the combination of L-dopa and hyoscine 
hydrobromide by oral route. The use of the combination of L-dopa 
and hyoscine hydrobromide by oral route in humans needs a safety 
evaluation. As part of a safety evaluation of combination of L-dopa 
and hyoscine hydrobrmide, a toxicological study was thus carried 
out to investigate its potential toxicity after repeated dose 90-day 
oral toxicity in Wistar rats of both sexes.  
MATERIALS AND METHODS 
Animals 
Adult Wistar rats (100±15 g) of both sexes, were maintained in the 
animal house of National Toxicology Centre, Pune. The animals were 
acclimatized to laboratory conditions for 7 d prior to the 
experiments. The rats were maintained at a room temperature of 
28±4˚C, with 70±10% relative humidity. During acclimatization, the 
animals were housed in polypropylene cages, with free access to 
normal diet and water ad libitum. The food pellets for the 
experimental animals were purchased from Nav Maharashtra 
Chakan Oil Mills (India). The animal studies were approved by the 
Institutional Animal Ethics Committee (IAEC) (IAEC/2010/PH35), 
Institute of Chemical Technology, Matunga, Mumbai.  
Drugs and solutions 
L-dopa obtained from Devi’s laboratory, Hyderabad and hyoscine 
hydrobromide procured from Sigma-Aldrich Co, St. Louis, MO with 
certificates of analysis were used in the present study. All other 
chemicals and biologicals, obtained from Sigma Chemical Co. (St. 
Louis, MO) were analytical grade with the highest purity. Solutions 
of L-dopa and hyoscine hydrobromide were prepared using distilled 
water and plain distilled water was used for administration of the 
animals under Control Group.  
Repeated-dose 90-day oral toxicity 
Adult Wistar rats were divided into 6 groups [Vehicle control, 
Therapeutic dose (TD), 2 times TD, 5 times TD, Reversal Control and 
Reversal Control of 5TD ] of 10 male and 10 females each. OECD 
guideline 408 [12] was followed for the study with small 
modification. Combination of L-dopa and hyoscine hydrobromide 
were administered different strength was administered orally for 90 
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consecutive days. Out of the 3 treatment groups, i.e. II, III and IV the 
animals of Group II were administered dose of lower therapeutic 
limit of both drugs (1H) i.e. 18 mg/kg of L-Dopa and 0.027 mg/kg of 
hyoscine hydrobromide, animals of the group III were administered 
twice the upper limit of the therapeutic dose of each drug (2H) i.e. 
108 mg/kg of L-dopa and 0.0675 mg/kg of hyoscine hydrobromide 
and animals of Group–IV were administered five times the upper 
limit of the therapeutic dose of each drug (5H) i.e. 540 mg/kg of L-
Dopa and 0.3375 mg/kg of hyoscine hydrobromide. Animals of the 
Group V were administered only vehicle. Animals of Group VI were 
administered the same dose as that of Group IV i.e. 540 mg/kg of L-
Dopa and 0.3375 mg/kg of hyoscine hydrobromide.  
Animals of reversal control and Reversal Control of 5TD were kept for 
additional 30 d (total 120 d) without any treatment with free access to 
water and feed ad libitum to study recovery or persistence of toxicity. 
Cage side observation, body weight, food and water consumptions 
were monitored throughout the study period. Animals were fasted 
overnight prior to collect blood samples by retro-orbital technique on 
day 91 and on 121 d for (Reversal control and Reversal Control of 5TD 
group). The blood samples were analysed for haematological 
(haematocrit, haemoglobin concentration, erythrocyte count, total and 
differential leukocyte count, platelet count) and biochemical (glucose, 
cholesterol, alkaline phophatase, alanine aminotransferase (ALT), 
aspartate transaminase (AST), creatinine, blood urea nitrogen, total 
protein, albumin etc.) parameters using Pathozyme smart-7 (Semi-
auto analyzer), BSA-3000 chemistry analyzer. After blood collection 
animals were sacrificed and subjected to gross necropsy. Once gross 
necropsy is done the organs like brain, lung, liver, heart, adrenal gland, 
kidney, uterus, ovaries, testis were surgically removed, weighed and 
stored for histopathological studies [13, 14]. 
Statistical analysis 
The results were expressed as mean±standard error of the mean 
(SEM). Statistical analysis was performed by one-way analysis of 
variance (ANOVA) followed by Bonferroni multiple comparison test 
as a post-ANOVA test to evaluate significant differences between 
groups. p<0.05 was considered statistically significant. All statistical 
analyses were carried out using the in statistical package (Graph Pad 













Fig. 1: Effects of oral administration of the L-dopa and 
hyoscine hydrobromide in combination for 90 d on mean 
body weights of male (A,B,C) and female (D,E,F). Body weight 
was calculated and data was expressed as mean of three 
replicates and±SD. The animals showed no significant 
differences in body weight between the control and treatment 
groups 
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Repeated dose 90-day oral toxicity 
The sub-chronic effect of L-dopa and hyoscine hydrobromide given 
on repeated dose 90 d at dose 540 mg/kg and 0.3375 mg/kg 
respectively in combination did not produce any mortality nor alter 
the behavior patterns of the Wistar rats during the observation 
period. The animals showed no significant differences in body 
weight between the control and treatment groups. Body weight 
increased gradually throughout the study period in males and 
females of all groups (fig. 1ABC and 1DEF).  
Behavior of the animal and food and water intake 
None of the rats belonging to different treatment groups showed 
any signs and symptoms of toxicity during cage side observation 
(Results not shown). There were no change in their skin, fur, 
eyes, gait and posture when compared to the vehicle control 
group. No signs of toxicity and mortality were observed on any 
of the administered dose when compared with the vehicle 
control group. Their food and water consumptions were also 
normal (Results not shown). 
Effect on the body weights 
In the sub-chronic repeated dose 90-day oral toxicity study, the 
combination of L-dopa and hyoscine hydrobromide at the TD, 2TD 
and 5TD did not produce significant change in body weight 
compared to the vehicle control group. In addition, there was no 
significant difference in reversal control and reversal high dose 
(5TD) (fig. 1ABC and 1DEF).  
 
Hematology 
The hematological investigation of repeated dose-90 d oral 
administration of the combination of L-dopa and hyoscine 
hydrobromide on hematological parameters in rats was studied. 
The analyzed hematological parameters for male (table 1) and female 
(table 2) rats included percent of total white blood cells (WBC), 
percent of lymphocytes (LY), percent of monocytes (MO), percent of 
granulocyte (GR) total red blood cells (RBC), platelet count, (HCT = 
hematocrit; HBG= hemoglobin), mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), red blood cell distribution width (RDW), 
Platelet hematocrit (PCT),platelets (PLT),mean platelet volume (MPV), 
platelet distribution width (PDW) using a hematology analyzer MEK-
6318K (Nihon Kohden Co., Ltd.). 
The hematological investigation of sub-chronic toxicity study 
demonstrated that there were no significant change in hematological 
parameters between vehicle treated and the combination of L-dopa 
and hyoscine hydrobromide treated groups of either male and female 
rats. However, the group of male rats receiving the formulation (2TD) 
had significantly (p<0.05) increased MCV and MCH levels than that of 
the vehicle treated group. Whereas, the group of female rats receiving 
TD and 2TD dose decreased MCHC (p<0.05) and granulocyte levels 
respectively and group of female rats receiving 2TD dose increased 
(p<0.05) lymphocyte levels. Both male and female rats at higher dose 
(5TD) showed no significant change in any hematological parameters 
hence, changes in hematological parameters in male and female rats at 
lower dose may not be due to effect of combination of L-dopa and 
hyoscine hydrobromide (table 1and 2).  
 
Table 1: Effects of sub-chronic 90 d oral administration of combination of L-dopa and hyoscine hydrobromide on hematological 
parameters in male rats 
Parameters Vehicle control Combination of L-DOPA and Scopolamine Reversal control group 5TD reversal group 
TD 2TD 5TD 
RBC (10[12]/l) 7.30±0.97 7.04±0.98 7.12±0.50 7.66±0.38 7.03±0.15 7.95±1.38 
HGB (g/l) 11.48±1.51 11.06±1.47 11.99±0.72 12.27±0.64 11.08±0.34 11.80±0.75 
HCT (%) 38.69±5.15 38.03±4.73 41.31±4.42 41.76±2.45 39.16±6.75 41.56±4.45 
MCV (fL) 53.14±2.73 54.32±3.88 58.1±4.65* 54.66±3.46 54.92±2.79 53.04±3.75 
MCH (pg) 15.69±0.38 15.66±0.44 16.8±1.00* 15.97±0.71 15.42±0.73 15.15±1.68 
MCHC (g/l) 29.66±1.16 29.04±1.73 29.12±1.70 29.25±1.05 30.54±2.37 28.28±1.63 
Platelet (109 517.90±8.92 /l) 454.20±10.86 526.70±6.90 530.70±9.07 523.00±11.87 563.20±13.14 
MPV (fL) 6.34±0.53 6.30±0.73 5.97±0.24 5.92±0.13 6.01±0.16 6.06±0.24 
PCT (%) 0.33±0.09 0.29±0.07 0.315±0.05 0.31±0.06 0.37±0.05 0.35±0.04 
WBC (109 10.62±2.24 /l) 11.38±2.51 10.22±2.76 10.94±3.54 11.44±2.18 11.21±2.13 
LYM (%) 61.78±9.96 60.46±15.53 68.63±9.51 65.32±12.01 72.12±2.49 65.26±11.67 
MON (%) 4.14±1.11 4.23±1.14 4.21±1.43 3.93±1.19 5.08±0.37 3.21±0.66 
GRAN (%) 34.08±9.26 35.31±14.47 27.16±8.41 30.75±11.21 29.71±0.86 21.53±10.90 
Note: Each value represents the mean±standard deviation (n=6) * P ˂ 0.05 comparison of group I with group II, III, IV using one-way ANOVA 
followed by Bonferroni multiple comparison test as a post-ANOVA test.  
 
Table 2: Effects of sub-chronic 90 d oral administration of combination of L-dopa and hyoscine hydrobromide on hematological 
parameters in female rats 
Parameters Vehicle control Combination of L-DOPA and Scopolamine Reversal control group 5TD reversal group 
TD 2TD 5TD 
RBC (10[12]/l) 7.37±0.93 7.25±0.71 8.07±1.02 7.18±1.47 7.18±1.00 7.32±0.62 
HGB (g/l) 11.73±1.24 11.82±1.02 12.17±0.63 11.72±2.46 11.37±1.04 11.85±1.02 
HCT (%) 39.44±3.82 42.44±5.09 43.01±3.82 41.09±9.98 38.19±5.04 40.41±3.16 
MCV (fL) 53.81±3.45 58.78±6.18 53.74±4.55 55.96±6.02 54.60±3.97 55.29±3.81 
MCH (pg) 15.92±0.96 16.29±0.94 15.21±1.61 16.24±0.91 15.64±2.34 16.04±0.82 
MCHC (g/l) 29.66±0.68 27.94±1.73* 28.38±1.82 29.25±1.63 28.63±1.59 29.47±1.09 
Platelet (109 556.70±114.70 /l) 637.80±145.07 527.30±108.48 443.60±108.04 531.40±52.87 497.8±99.07 
MPV (fL) 5.98±0.33 6.31±0.61 5.96±0.29 6.21±0.63 6.31±0.23 6.28±0.42 
PCT (%) 0.34±0.09 0.41±0.13 0.341±0.14 0.27±0.07 0.40±0.11 0.33±0.06 
WBC (109 11.72±2.87 /l) 13.25±2.05 11.07±1.65 12.17±3.30 11.08±0.71 9.87±1.78 
LYM (%) 57.01±13.23 67.96±20.68 76.29±10.13* 60.33±21.94 60.81±14.95 68.97±9.38 
MON (%) 4.93±2.52 4.17±2.44 3.38±1.04 4.59±2.03 4.18±1.80 3.81±1.08 
GRAN (%) 38.06±11.94 27.87±19.48 20.33±9.19* 35.08±20.20 28.97±6.91 26.95±9.09 
Note: Each value represents the mean±standard deviation (n=6) * P ˂ 0.05 comparison of group I with group II, III, IV using one-way ANOVA 
followed by Bonferroni multiple comparison test as a post-ANOVA test. 
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Table 3: Effects of sub-chronic 90 d oral administration of combination of L-dopa and hyoscine hydrobromide on biochemical parameters 
in male rats 
Parameters Vehicle control Combination of L-DOPA and Scopolamine Reversal control group 5TD reversal group 
TD 2TD 5TD 
Glucose 128.60±15.50 132.70±20.64 157.90±32.37* 137.70±14.30 133.7±17.47 149.00±18.35 
Creatinine 0.58±0.08 0.59±0.13 0.62±0.14 0.55±0.07 0.58±0.08 0.58±0.07 
Urea 27.75±2.17 25.97±6.68 24.27±4.99 26.57±4.02 27.07±2.72 23.87±2.57 
Total protein 7.46±0.54 7.22±0.67 7.72±0.61 7.69±0.62 7.66±0.44 8.07±0.19 
SGPT 64.40±8.36 55.60±15.51 61.70±16.72 62.70±9.14 67.22±9.46 58.82±3.53 
SGOT 107.04±17.42 107.50±19.29 111.70±16.92 121.53±11.73 104.3±20.03 116.2±19.33 
ALP 410.70±136.81 366.70±132.43 431.70±216.40 492.50±141.21 398.98±91.45 313.18±105.74 
T. Bilirubin 7.40±3.56 7.279±3.09 4.231±1.40* 4.36±2.68* 7.61±0.16 4.15±0.21* 
Note: Each value represents the mean±standard deviation (n=6) * P ˂  0.05 comparison of group I with group II, III, IV using one-way ANOVA 
followed by Bonferroni multiple comparison test as a post-ANOVA test. 
 
Table 4: Effects of sub-chronic 90 d oral administration of combination of L-dopa and hyoscine hydrobromide on biochemical parameters 
in female rats 
Parameters Vehicle control Combination of L-DOPA and Scopolamine Reversal control group 5TD reversal group 
TD 2TD 5TD 
Glucose 166.90±49.26 135.60±28.69 134.30±26.05 149.90±38.19 169.80±34.74 162.40±21.20 
Creatinine 0.61±0.14 0.60±0.09 0.55±0.07 0.57±0.07 0.58±0.07 0.59±0.05 
Urea 28.11±4.86 26.11±3.76 29.56±5.07 25.98±3.69 26.80±2.07 25.92±3.00 
Total protein 8.30±0.61 6.98±0.54** 7.95±0.74 7.86±0.79 8.32±0.78 8.05±0.53 
SGPT 63.80±7.41 56.00±8.89 63.8±12.76 64.60±10.39 60.79±6.33 63.88±12.19 
SGOT 94.39±22.78 108.78±14.13 111.80±20.60 122.25±17.11** 95.10±16.88 122.90±16.99** 
ALP 410.20±110.13 412.40±154.40 269.70±64.45* 351.30±122.26 351.19±62.98 322.65±87.65 
T. Bilirubin 7.29±3.58 4.10±1.43** 4.419±1.56* 3.61±1.12** 7.43±0.23 4.409±0.14** 
Note: Each value represents the mean±standard deviation (n=6) * P ˂ 0.05, ** P ˂ 0.01 comparison of group I with group II, III, IV, using one-way 
ANOVA followed by Bonferroni multiple comparison test as a post-ANOVA test. 
 
Chemical chemistries 
Blood biochemistry analysis was done on serum from blood samples 
collected in separator tubes using a BS-200 automatic biochemistry 
analyzer (Mindary Co., Ltd.) including glucose (Glu), creatinine (Cr), 
total protein (TP), serum glutamic-pyruvic transaminase (SGPT) and 
alkaline phosphatase (ALP) total bilirubin (TB). 
Blood biochemistry analysis of male and female rats showed no 
significant change in serum biochemical parameters between 
vehicle treated and the combination of L-DOPA and hyoscine 
hydrobromide treated group except few. Male rats treated at 2TD 
dose showed an increase (p<0.05) in glucose level and at 2TD, 5TD, 
5TD reversal group showed decrease (p<0.05) in T. bilirubin level. 
Female rats showed significant (p<0.05) decrease T. bilirubin level 
in TD (p<0.01), 2TD (p<0.05), 5TD (p<0.01), 5TD reversal group 
whereas decrease in total protein (p<0.01) and ALP (p<0.05) level at 
2TD. Female rats also showed significant increase (p<0.01) in SGOT 
level at 5TD and 5TD reversal group. The changes in glucose level in 
male rats and ALP, total protein levels in female rats are not 
significant at higher dose (5TD) hence, these changes may not be 
due to the effect of drug (table 3 and 4). 
Macroscopic and histological observations 
Histopathological examination showed that, all the organs were 
normal and did not show any pathological changes. The histological 
pictures of some of the important organs were shown in figure. 
Taken together, body weight, hematological and biochemical 
parameters and histological data indicate that there is no toxicity in 
chronic study of the combination at any of the administered dose 
(fig. 2).  
DISCUSSION  
The concomitant and growing use of combination of traditional 
medicine with modern medicine in the present age has necessitated 
the thorough evaluation of safety and efficacy of the combination 
therapy [15]. Keeping in view the necessity of evaluation of safety 
and efficacy of the combination therapy, the present chronic toxicity 
study was carried out for the combination of L-dopa and hyoscine 
hydrobromide. The present 90 d chronic toxicity study was done to 
evaluate the possible health hazard likely from repeated exposure 
over a relatively long period of time. 
 
 
Fig. 2: Histopathological examination of Brain, Heart, Liver, 
Kidney and Testes/Ovaries from normal control male (NCM), 
normal control female (NCF) rats, High Dose treated male 
(HDM) and High Dose treated female (HDF) rats by hematoxylin 
and eosin staining 100 X zoom 
 
None of the rats belonging to different treatment groups showed 
any signs and symptoms of toxicity during cage side observation 
(Results not shown). There were no change in their skin, fur, eyes, 
gait and posture when compared to the vehicle control group. No 
signs of toxicity and mortality are observed on any the 
administered dose when compared with the vehicle control group. 
Their food and water consumptions were also normal (Results not 
shown). All the treated groups gained weight during the study 
period and absence of significant changes in body weight 
suggested that the combination is fairly nontoxic. Gross necropsy 
finding also did not reveal any adverse effect in organ and hence 
combination is said to be safe [16, 17]. 
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Blood is an important physiological and pathological status in 
animals and humans. Normally the parameters measured are RBC, 
platelets, WBC, differentiated leukocyte count, hematocrit, and 
hemoglobin. Toxicity induced by drugs can alter the normal range of 
these hematological parameters [18-20]. The haematological 
parameters of rats treated with TD, 2TD, 5TD and 5TD reversal 
group were comparable to that of the vehicle control group. Except, 
2TD in male rats dose showed a significant increase in MCV and 
MCH levels whereas TD and 2TD decreased MCHC and granulocyte 
levels and 2TD dose increased the Lymphocyte levels. Female rats 
showed a significant decrease in MCH levels. Although these 
haematological parameters showed statistically significant 
difference but these differences are not dose related. Hence, these 
may be the result of some biological variation rather than the 
treatment effect.  
Analysis of serum biochemical parameters is relevant for risk 
evaluation, as any changes in the biochemical system have higher 
predictive value for human toxicity when data are transferred from 
animal studies to human [21]. The Biochemical parameters of rats 
treated with different doses of combination of L-dopa and hyoscine 
hydrobrmide instead of were comparable to that of the vehicle 
control group. Except, male rats and female rats showed a significant 
decrease in T. bilirubin level and female rats showed a significant 
increase in SGOT levels.  
SGOT and SGPT are trustworthy markers of liver parenchymal injury 
[22]. The increase in the level of SGOT and SGPT in serum may be 
due to leakage of these enzymes from liver cytosol into the blood 
stream [23]. The SGOT levels in female rats at 5TD and 5TD reversal 
group were significantly higher than vehicle treated animals 
indicating liver dysfunction [24]. The bilirubin concentration in the 
serum indicates the secretory and synthetic functioning of the liver 
and can be used to determine liver damage. Bilirubin is the major 
breakdown product of red blood cells. It is removed from the body 
by liver; hence it can be used as an indicator of liver toxicity. 
Increase in bilirubin concentration indicates increased production of 
bilirubin or decreased liver uptake (a result of liver toxicity).  
The results of the study showed that the word combination of 
containing L-Dopa and Hysocine HBr significantly decreased the 
total bilirubin levels when compared to the vehicle control group. 
This observation along with normal microscopic data of animals 
from treated suggests that the formulation had no adverse effect on 
liver [25]. There were some more changes in biochemical 
parameters in male and female rat’s viz. glucose and ALP. These 
changes were not reflected in the higher dose. Hence, may not be 
because of the drug but may be due to some other variation. The 
results of the study suggested that chronic administration of the 
formulation of L-DOPA and Hyoscine HBr produced no significant 
toxic effects in male and female Wistar rats, which could stand as an 
assurance for its medicinal use.  
CONCLUSION 
In Conclusion, the 90 d chronic oral toxicity of L-DOPA and Hyoscine 
HBr formulation is well tolerated in rats. The No-Observed-Adverse-
Effect Level (NOAEL) for formulation is 5TD, the highest doses 
tested in male and female rats. 
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